Menu
GeneBe

rs79660178

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong

The NM_000492.4(CFTR):c.366T>A(p.Tyr122Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: not found (cov: 32)

Consequence

CFTR
NM_000492.4 stop_gained

Scores

2
3
2

Clinical Significance

Pathogenic reviewed by expert panel P:7

Conservation

PhyloP100: 0.856
Variant links:
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 7-117530991-T-A is Pathogenic according to our data. Variant chr7-117530991-T-A is described in ClinVar as [Pathogenic]. Clinvar id is 38833.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr7-117530991-T-A is described in Lovd as [Pathogenic]. Variant chr7-117530991-T-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
CFTRNM_000492.4 linkuse as main transcriptc.366T>A p.Tyr122Ter stop_gained 4/27 ENST00000003084.11

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
CFTRENST00000003084.11 linkuse as main transcriptc.366T>A p.Tyr122Ter stop_gained 4/271 NM_000492.4 P2P13569-1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
31
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Cystic fibrosis Pathogenic:4
Pathogenic, reviewed by expert panelresearchCFTR2Mar 17, 2017- -
Pathogenic, criteria provided, single submittercurationCFTR-FranceJan 29, 2018- -
Pathogenic, criteria provided, single submitterclinical testingCounsylFeb 02, 2016- -
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJul 18, 2022The p.Y122* pathogenic mutation (also known as c.366T>A and p.Y122X), located in coding exon 4 of the CFTR gene, results from a T to A substitution at nucleotide position 366. This changes the amino acid from a tyrosine to a stop codon within coding exon 4. This mutation was first reported in a 5 year old French male with classic cystic fibrosis and pancreatic insufficiency, who also carried deltaF508 (Chevalier-Porst F et al. Hum Mol Genet, 1992 Nov;1:647-8). Another paper reported this as a founder mutation on the French Reunion Island in the Indian Ocean, where 30% of the cystic fibrosis patients studied were either homozygous for this mutation or compound heterozygous with the pathogenic p.F508del mutation (deltaF508) (Duguépéroux I et al. J Cyst Fibros, 2004 Aug;3:185-8). Functional in vitro studies found that cells carrying this pathogenic mutation had elevated sweat chloride levels and decreased lung function (Sosnay PR et al. Nat Genet, 2013 Oct;45:1160-7). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
not provided Pathogenic:2
Pathogenic, no assertion criteria providedclinical testingDiagnostic Laboratory, Department of Genetics, University Medical Center Groningen-- -
Pathogenic, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
CFTR-related disorder Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Mar 17, 2017- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.63
D
BayesDel_noAF
Pathogenic
0.38
Cadd
Pathogenic
33
Dann
Uncertain
0.99
Eigen
Uncertain
0.21
Eigen_PC
Benign
-0.028
FATHMM_MKL
Uncertain
0.84
D
MutationTaster
Benign
1.0
A;A
Vest4
0.93
GERP RS
0.57

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs79660178; hg19: chr7-117171045; API